LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week^® (DDW) 2025 conference, taking place May 5, 2025.

The CLARITI study was selected as one of only six abstracts to be presented at the AGA Institute Council’s Pancreatic Disorders Section Distinguished Abstract Plenary—an honor reserved for research demonstrating exceptional scientific and clinical impact.

Dr. Aimee Lee Lucas, Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai Morningside Hospitals and Professor of Medicine at Icahn School of Medicine, will present the CLARITI study findings at DDW 2025. Her presentation, titled “Clinical validation of a novel blood-based multi-biomarker test for the early detection of pancreatic ductal adenocarcinoma (PDAC) in an independent high-risk population shows similar high performance as observed in its model development study,” highlights the study’s robust methodology and the strong performance of Immunovia’s next-generation test.

As a member of the Immunovia Scientific Advisory Board, Dr. Lucas was integral to the study’s design and played a key role in the collection of blood samples.

“I am excited to present these data at the world’s largest conference for gastroenterologists. Selection of these study results for a distinguished plenary oral presentation underscores the rigor of the CLARITI validation study and the strong performance of the Immunovia test in the study,” says Dr. Aimee Lee Lucas.

“We are very proud to see the CLARITI study receive this remarkable recognition. It’s a strong statement about the quality of our science and it highlights the importance of the unmet clinical need our new test addresses,” says Jeff Borcherding, Immunovia CEO.

About Digestive Disease Week
Digestive Disease Week^® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and other professional societies, DDW is an in-person and online meeting from May 3-6, 2025. The meeting is expected to include more than 13,000 attendees encompassing global researchers, clinicians and key decision-makers in gastroenterology and hepatology.

For further information, please contact

Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Karin Almqvist Liwendahl, CFO
karin.almqvist.liwendahl@immunovia.com  
+46 70 911 56 08

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.